H. Richard Alexander named chief surgical officer at Rutgers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rutgers Cancer Institute of New Jersey appointed H. Richard Alexander as its new chief surgical officer. He is also appointed as a professor of surgery in the Division of Surgical Oncology at Rutgers Robert Wood Johnson Medical School.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The Friends of Cancer Research annual meeting, to be held Nov. 4 in Washington, DC, will focus on three questions facing the field of oncology clinical trial design: How do clinical researchers create seamless trial designs for drug development in rare cancers?What are the considerations for clinical trial design testing combination drug development? How can clinical researchers address variability in standards of care in multi-regional clinical trials?
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login